Industry Collaboration

StratCan serves as an umbrella organisation and single point of entry to the cancer research community at KI. Representing the large cancer research community at KI, we aim to facilitate the launching of collaborative projects with industrial partners in jointly defined interest areas.

Corporate partnering

StratCan works closely with Richard Cowburn, Responsible for Corporate Partnering at KI, to strengthen and develop fruitful long-term collaborations in the cancer space between KI the pharma industry. These efforts will strengthen the ongoing collaboration between several individual research groups and companies, aim to give rise to new collaborations, and allow for a more coordinated approach towards interaction with the industrial sector.

KI-Roche Master Collaborative Agreement

The Master Collaborative Agreement (MCA) for strategic collaboration in the Cancer Research field was signed by KI and Roche global research organization in December 2014. The aim is to develop new and better therapies and more specific methods for analyses, but also to identify novel signal pathways that can be targets for future drugs.

Article regarding the MCA in (in Swedish)

Joint Steering Committee (JSC):

Members: Astrid Kiermaier (Roche), Pavel Pisa (Roche), Rune Toftgård (KI) and Klas Wiman (KI). Chair: Gabriele Beer (Roche).

Alliance Directors: Björn Arvidsson (Roche) and Sandra Falck (KI).

The Joint Steering Committee meets regularly (2-4 times yearly).

Please, do not hesitate to contact the alliance directors or any other member of the JSC should you have any questions or want more information regarding the collaboration agreement and possibilities for joint research projects.

KI-Roche Oncology workshop:

The first joint KI-Roche workshop in Oncology was held at Nobel Forum KI Solna October 19-20, 2015 with the ambition to allow interaction and discussion regarding possibilities for joint research projects.

Content reviewer:
Dina Dabaghie